Praxis Precision expects to submit two NDAs around mid-February for its essential tremor candidate ulixacaltamide hydrochloride and the epilepsy asset relutrigine, with both applications being days apart and no missing components. The company is evaluating a Priority Review request to optimize FDA workload and benefits without delaying filings.

Praxis estimates essential tremor affects 2–2.5% of the US population, translating to 1–2 million actively treated patients and roughly 80,000 monthly prescriptions from neurologists. Management views $40,000–60,000 annual pricing as a potential sweet spot, while noting 70% of patients have familial links that could expand market engagement.

In its epilepsy program, Praxis highlights relutrigine targeting SCN2A/SCN8A mutations with a smaller NDA package due to fewer studies, alongside the EMERALD developmental and epileptic encephalopathies trial expected to read out in H2 2026. The company also plans an elsunersen NDA next year, expanding its central nervous system pipeline.

Praxis holds approximately $1.5 billion in cash, funding operations into 2028 and supporting launch preparations including field force sizing, broad geographic coverage and payer/copay assistance. Executives emphasize rapid patient recruitment—5–7 times faster than peers—as a competitive advantage for commercialization and patient outreach.